Get the Stockscreener App
2.16
1.82%
-0.04
After Hours:
2.15
-0.01
-0.46%
Oramed Pharmaceuticals Inc Stock (ORMP) Forecast
The Oramed Pharmaceuticals Inc (ORMP) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $2.1051, representing a -2.54% decrease from the current price of $2.16. The highest analyst price target is $2.3312, and the lowest is $1.879.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month ORMP Price Target
Average 6.1271
(+183.66% Upside)
Is Oramed Pharmaceuticals Inc (ORMP) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 41.14 | Neutral |
| STOCH(9,6) | 20.01 | Neutral |
| STOCHRSI(14) | 21.13 | Neutral |
| MACD(12,26) | -0.0367 | Sell |
| ADX(14) | 20.47 | Neutral |
| William %R | -74.98 | Neutral |
| CCI(14) | -57.85 | Neutral |
Buy: 0
Sell: 1
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
2.25
Sell
|
2.2333
Sell
|
| MA20 |
2.347
Sell
|
2.2736
Sell
|
| MA50 |
2.2834
Sell
|
2.2996
Sell
|
| MA100 |
2.3305
Sell
|
2.3235
Sell
|
| MA200 |
2.3717
Sell
|
2.3716
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, ORMP could be considered a Strong Sell, with 17 technical analysis indicators signaling 0 Buy signals, 11 signaling Sell signals and 6 Neutral signals. This might not be a good time to consider opening new positions on ORMP, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 41.14 indicates that ORMP is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 20.01 indicates that ORMP is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 21.13 indicates that ORMP is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 20.47 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -57.85 indicates that ORMP is still oversold but not to an extreme extent.
Long-term ORMP price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Oramed Pharmaceuticals Inc financial reports and earnings history, Oramed Pharmaceuticals Inc (ORMP) stock could reach $1.7079 by 2030, $0.0878 by 2040 and $6.2259 by 2050. See the projected annual prices until 2050 of the Oramed Pharmaceuticals Inc stock below:
- Oramed Pharmaceuticals Inc (ORMP) is expected to reach an average price of $0.6836 in 2035, with a high prediction of $0.8036 and a low estimate of $0.1772. This indicates an $-68.35% rise from the last recorded price of $2.16.
- Oramed Pharmaceuticals Inc (ORMP) stock is projected to chart a bullish course in 2040, with an average price target of $0.0682, representing an $-96.84% surge from its current level. The forecast ranges from a conservative $0.1414 to a sky-high $0.0878.
- Our analysts predict Oramed Pharmaceuticals Inc (ORMP) to jump 30.18% by 2045, soaring from $2.732 to an average price of $2.812, potentially reaching $5.6792. While $2.732 is the low estimate, the potential upside is significant.
- Oramed Pharmaceuticals Inc (ORMP) stock is expected to climb by 2050, reaching an average of $5.4918, a $154.25% jump from its current level. However, a wide range of estimates exists, with high and low targets of $6.2259 and $4.1265, respectively, highlighting the market's uncertainty.
Oramed Pharmaceuticals Inc Stock (ORMP) Year by Year Forecast
Oramed Pharmaceuticals Inc Stock (ORMP) Price Forecast for 2025
Oramed Pharmaceuticals Inc Stock (ORMP) is expected to reach an average price of $3.261 in 2025, with a high prediction of $5.0609 and a low estimate of $1.461. This indicates an +50.97% rise from the last recorded price of $2.16.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2025 | $2.0622 | $1.879 | $2.3312 | -4.53% |
| June, 2025 | $2.3765 | $1.9154 | $2.6665 | +10.02% |
| July, 2025 | $3.1518 | $2.1386 | $3.4407 | +45.92% |
| August, 2025 | $2.3761 | $2.3361 | $3.2329 | +10.00% |
| September, 2025 | $2.9003 | $2.3771 | $3.2982 | +34.27% |
| October, 2025 | $2.2756 | $2.1356 | $3.0914 | +5.35% |
| November, 2025 | $1.6699 | $1.5999 | $2.4167 | -22.69% |
| December, 2025 | $1.5952 | $1.461 | $2.0242 | -26.15% |
Oramed Pharmaceuticals Inc Stock (ORMP) Price Forecast for 2026
The predicted value for Oramed Pharmaceuticals Inc (ORMP) in 2026 is set at an average of $12.45. Estimates vary from a peak of $23.37 to a trough of $1.5334, indicating an +476.46% surge from the present price of $2.16.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $3.5195 | $1.5334 | $4.2195 | +62.94% |
| February, 2026 | $3.3037 | $2.6216 | $4.6505 | +52.95% |
| March, 2026 | $3.448 | $3.1969 | $3.8159 | +59.63% |
| April, 2026 | $9.6933 | $3.3141 | $10.79 | +348.76% |
| May, 2026 | $8.2476 | $6.0654 | $9.4544 | +281.83% |
| June, 2026 | $8.9018 | $8.4086 | $11.82 | +312.12% |
| July, 2026 | $9.3972 | $7.294 | $10.89 | +335.05% |
| August, 2026 | $13.27 | $9.3482 | $14.27 | +514.42% |
| September, 2026 | $11.41 | $10.49 | $13.65 | +428.09% |
| October, 2026 | $17.34 | $10.67 | $17.86 | +702.82% |
| November, 2026 | $18.80 | $13.13 | $22.68 | +770.15% |
| December, 2026 | $21.12 | $16.91 | $23.37 | +877.80% |
Oramed Pharmaceuticals Inc Stock (ORMP) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Oramed Pharmaceuticals Inc (ORMP) is $16.71, with a high forecast of $30.67 and a low forecast of $2.7563. This indicates an +673.69% increase from the last price of $2.16.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $21.76 | $19.20 | $23.08 | +907.63% |
| February, 2027 | $25.63 | $21.53 | $30.67 | +1,087% |
| March, 2027 | $14.53 | $12.73 | $25.58 | +572.89% |
| April, 2027 | $10.19 | $9.8587 | $14.94 | +371.70% |
| May, 2027 | $10.46 | $6.6608 | $11.01 | +384.39% |
| June, 2027 | $8.0782 | $7.9682 | $11.94 | +273.99% |
| July, 2027 | $7.8025 | $7.5293 | $9.5604 | +261.23% |
| August, 2027 | $4.9268 | $4.9068 | $8.3346 | +128.09% |
| September, 2027 | $4.0721 | $2.8999 | $5.1878 | +88.52% |
| October, 2027 | $2.8863 | $2.7563 | $4.1953 | +33.63% |
| November, 2027 | $7.3706 | $2.9574 | $7.9706 | +241.23% |
| December, 2027 | $8.6559 | $6.5017 | $11.35 | +300.74% |
Oramed Pharmaceuticals Inc Stock (ORMP) Price Forecast for 2028
In 2028, Oramed Pharmaceuticals Inc (ORMP) is projected to reach an average price of $6.9725, with a high projection of $12.93 and a low estimate of $1.0136. This indicates an +222.80% rise from the last price of $2.16.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $7.3502 | $7.2402 | $9.637 | +240.29% |
| February, 2028 | $5.6644 | $5.5844 | $8.1323 | +162.24% |
| March, 2028 | $6.2997 | $4.9366 | $6.4447 | +191.65% |
| April, 2028 | $7.604 | $5.2719 | $8.9029 | +252.04% |
| May, 2028 | $10.15 | $7.0461 | $10.48 | +369.88% |
| June, 2028 | $1.2636 | $1.0136 | $12.93 | -41.50% |
| July, 2028 | $1.3778 | $1.0946 | $1.4578 | -36.21% |
| August, 2028 | $1.1632 | $1.0932 | $1.5222 | -46.15% |
| September, 2028 | $1.3874 | $1.0642 | $1.4942 | -35.77% |
| October, 2028 | $2.0017 | $1.3285 | $2.2813 | -7.33% |
| November, 2028 | $3.247 | $1.9377 | $4.4749 | +50.32% |
| December, 2028 | $2.8113 | $2.3302 | $3.3881 | +30.15% |
Oramed Pharmaceuticals Inc Stock (ORMP) Price Forecast for 2029
The 2029 price forecast for Oramed Pharmaceuticals Inc Stock (ORMP) is $1.9337 on average, with a high prediction of $2.9438 and a low estimate of $0.9236. This represents an -10.48% decrease from the previous price of $2.16.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $2.6266 | $2.147 | $2.8323 | +21.60% |
| February, 2029 | $2.4808 | $2.0798 | $2.8576 | +14.85% |
| March, 2029 | $2.2851 | $2.0951 | $2.863 | +5.79% |
| April, 2029 | $1.4293 | $1.2693 | $2.2762 | -33.83% |
| May, 2029 | $1.1747 | $0.9236 | $1.5104 | -45.62% |
| June, 2029 | $1.3889 | $1.1257 | $1.5479 | -35.70% |
| July, 2029 | $1.5732 | $1.3571 | $1.7411 | -27.17% |
| August, 2029 | $2.2635 | $1.3664 | $2.5585 | +4.79% |
| September, 2029 | $2.7328 | $1.8506 | $2.7828 | +26.52% |
| October, 2029 | $2.1881 | $1.927 | $2.9438 | +1.30% |
| November, 2029 | $1.5523 | $1.4223 | $2.4191 | -28.13% |
| December, 2029 | $1.3137 | $1.2774 | $1.7645 | -39.18% |
Oramed Pharmaceuticals Inc Stock (ORMP) Price Forecast for 2030
Oramed Pharmaceuticals Inc Stock (ORMP) is expected to reach an average price of $2.20 in 2030, with a high forecast of $4.0719 and a low forecast of $0.3281. This signifies an +1.85% surge from the last price of $2.16.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $1.468 | $0.7638 | $1.7079 | -32.04% |
| February, 2030 | $1.2846 | $1.1044 | $1.7123 | -40.53% |
| March, 2030 | $1.5191 | $1.2687 | $2.0287 | -29.67% |
| April, 2030 | $1.3066 | $1.0693 | $1.5572 | -39.51% |
| May, 2030 | $1.2342 | $0.7878 | $1.34 | -42.86% |
| June, 2030 | $1.1427 | $0.9664 | $1.3638 | -47.10% |
| July, 2030 | $0.5834 | $0.3281 | $1.3649 | -72.99% |
| August, 2030 | $3.3685 | $0.6155 | $4.0719 | +55.95% |
| September, 2030 | $3.2205 | $2.5504 | $3.9104 | +49.10% |
| October, 2030 | $2.8611 | $2.7211 | $3.7447 | +32.46% |
| November, 2030 | $1.1096 | $1.0496 | $3.3053 | -48.63% |
| December, 2030 | $1.0581 | $0.5617 | $1.3117 | -51.01% |
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):